Effects of Botulinum Toxin Injection Combined with RESWT in Lower Extremity Spasticity in Children with Cerebral Palsy

NCT ID: NCT06494618

Last Updated: 2025-03-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-31

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to check and compare the effects of botulinum toxin injection combined with shock wave therapy versus botulinum toxin injection only for lower extremity spasticity in children with cerebral palsy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

20 pediatric patients diagnosed with cerebral palsy who received botulinum toxin type A injection for lower extremity spasticity were divided into two groups. The first group will receive only conventional treatment after the injection, while the second group will receive extracorporeal shockwave therapy for injected muscles. The shock wave therapy is planned as 3 sessions per week, starting one week after the injection. Patients will be compared in terms of MAS scores, MTS scores, passive joint range of motion, modified timed up and go test, pain scores, (faces pain scale-revised) and Goal Attainment Scaling scores. Patients will be evaluated 1 week, 1 month and 3 months after the injection with pre-injection data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Palsy, Spastic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Pediatric patients diagnosed with cerebral palsy who received botulinum toxin injection for lower extremity spasticity were randomized two groups. The first group will receive only conventional treatment after the injection, while the second group will receive extracorporeal shockwave therapy for injected muscles and their routine conventional therapy. The shock wave therapy is planned as 3 sessions per week, starting one week after the injection.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
Outcomes Assessor were blinded to patients who received shockwave therapy and who did not received.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Botulinum Toxin Injection and Conventional Therapy

The group received conventional therapy (such as stretching exercises) after Botulinum Toxin Type A Injection for spastic lower extremity muscle groups.

Group Type NO_INTERVENTION

No interventions assigned to this group

Botulinum Toxin Injection and Shockwave Therapy

The group received extracorporeal shockwave therapy conventional therapy (such as stretching exercises). Shockwave therapy is planned 3 sessions, starting first week after injection. It is planned to apply 1500 pulses, 4 hertz, 2 bars radial eswt to the injected spastic muscle groups in each session. The patients in this group will continue to their conventional therapy like the first group.

Group Type ACTIVE_COMPARATOR

Radial Extracorporeal Shockwave Therapy

Intervention Type DEVICE

1500 pulses, 4 hertz, 2 bar radial extracorporeal shockwave therapy targeted muscle belly for botulinum toxin injected lower extremity muscle groups. 3 sessions were planned once a week, starting from first week after injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radial Extracorporeal Shockwave Therapy

1500 pulses, 4 hertz, 2 bar radial extracorporeal shockwave therapy targeted muscle belly for botulinum toxin injected lower extremity muscle groups. 3 sessions were planned once a week, starting from first week after injection.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with cerebral palsy.
* Spasticity in at least one of the lower extremity muscle groups.
* No contraindications to shockwave therapy.
* Applied Botulinum Toxin Type A injection for at least one spastic muscle of lower extremity.
* Agreed to participate to study (patient/primary caregiver)

Exclusion Criteria

* Surgery history within the last year of the muscle to be injected and treated
* Having uncontrolled epilepsy.
* Having infection
* Coagulopathy
Minimum Eligible Age

2 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istanbul Medeniyet University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bilinç Doğruöz Karatekin

Bilinc Dugruoz Karatekin, M.D., Department of Physical Medicine and Rehabilitation

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Belgin Erhan, Assoc. Prof.

Role: STUDY_DIRECTOR

Istanbul Medeniyet University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istanbul Medeniyet University Goztepe Prof. Dr. Suleyman Yalcin City Hospital

Istanbul, Kadikoy, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ismail Hakan Akbulut, Resident

Role: CONTACT

+905549151240

Belgin Erhan, Assoc. Prof.

Role: CONTACT

+905322678024

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ismail Hakan Akbulut, Resident

Role: primary

+905549151240

Belgin Erhan, Assoc. Prof.

Role: backup

+905322678024

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP BTX ESWT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.